| abstract |
The invention relates to 3 hybridoma cell lines, namely BE-8 (CNCM-Nr.I / 913), BE-4 (CNCM-Nr.I / 911) and BF-6 (CNCM-Nr.I / 912), which by Fusion of immunized mouse spleen cells with mouse myeloma cells is available after the spleen cells were immunized against interleukin-6 before the fusion. These 3 cell lines produce monoclonal antibodies which recognize human interleukin-6 and, depending on the different cell lines, each form a different epitope on the interleukin-6 molecule.n n n The monoclonal antibodies can be coupled to toxins and / or chemotherapeutic agents and can be used in the manufacture of a composition for the therapy, prophylaxis and diagnosis of interleukin-6-dependent diseases. |